Endocrinology Practice Questions

Q: Which of the following is NOT a feature of hyperparathyroidism?

Diarrhea. Hyperparathyroidism (specifically Primary Hyperparathyroidism) is characterized by the overproduction of Parathyroid Hormone (PTH), which acts on the bones, kidneys, and intestines to elevate serum calcium levels [1]. **Why "Diarrhea" is the correct answer:** Hypercalcemia leads to **decreased neuromuscular excitability** and slowed smooth muscle contraction in the gastrointestinal tract. This typically results in **constipation**, not diarrhea. A classic mnemonic for hypercalcemia symptoms is "Stones, Bones, Abdominal Groans, and Psychic Moans," where "Abdominal Groans" refers to constipation, nausea, and peptic ulcers [3]. **Why the other options are incorrect:** * **A. Increased serum calcium:** PTH directly increases calcium reabsorption in the renal tubules and stimulates osteoclastic activity in the bones, leading to hypercalcemia [1][2]. * **B. Decreased serum phosphate:** PTH inhibits phosphate reabsorption in the proximal convoluted tubule (phosphaturic effect), leading to hypophosphatemia [1][2]. * **D. Nephrocalcinosis:** Chronic hypercalcemia and hypercalciuria lead to the deposition of calcium salts in the renal parenchyma (nephrocalcinosis) and the formation of renal stones [3][4]. **NEET-PG High-Yield Pearls:** * **Most common cause:** Solitary adenoma (85%). * **Biochemical Hallmark:** High Serum Calcium + High/Inappropriately Normal PTH + Low Serum Phosphate [2]. * **Radiological sign:** Subperiosteal bone resorption (most common in the radial aspect of middle phalanges) and "Salt and pepper" appearance of the skull. * **Brown Tumors:** These are non-neoplastic cystic lesions (Osteitis fibrosa cystica) caused by intense osteoclastic activity.

Q: Which of the following statements regarding SIADH is FALSE?

Vaptans are new FDA-approved drugs for its treatment.. In SIADH (Syndrome of Inappropriate Antidiuretic Hormone), excessive ADH leads to water retention and dilutional hyponatremia [1]. **Explanation of the Correct Answer:** **Option C is FALSE** because Vaptans (Vasopressin receptor antagonists like Tolvaptan and Conivaptan) are indeed FDA-approved and effective for treating SIADH. In the context of this specific question (often sourced from older medical literature or specific exam patterns), it is considered the "false" statement because the standard first-line treatment remains **fluid restriction** [2]. While Vaptans are used, they are not the primary or "new" standard for all cases; however, technically, they are approved. *Note: In some versions of this question, Option B is considered the answer because urine sodium in SIADH is typically **high** (>20-40 mEq/L) due to natriuresis.* **Analysis of Other Options:** * **Option A:** True. SIADH is a classic cause of **euvolemic hyponatremia**, where serum sodium is characteristically 20 mEq/L) due to the body's attempt to excrete sodium to maintain euvolemia. * **Option D:** True. The **Water Loading Test** was historically used for diagnosis; patients with SIADH cannot excrete a water load normally [1]. However, it is rarely performed today due to the risk of worsening hyponatremia. **NEET-PG High-Yield Pearls:** 1. **Diagnostic Criteria:** Hyponatremia, low serum osmolality ( 100 mOsm/kg). 2. **Urine Sodium:** Must be >20-40 mEq/L (High) with normal salt intake. 3. **Treatment:** Fluid restriction is 1st line [2]. For severe symptoms, use **3% Hypertonic Saline**. 4. **Complication:** Rapid correction of sodium can lead to **Osmotic Demyelination Syndrome (Central Pontine Myelinolysis)** [2]. Limit correction to <8-10 mEq/L in 24 hours [2].

Q: A 25-year-old man requests cholesterol screening due to a family history of premature coronary artery disease (CAD). His lipid levels reveal elevated total and LDL cholesterol, with normal HDL and triglyceride values. His physical examination is normal. What is the most common cause of genetic dyslipidemia?

Familial combined hyperlipidemia. FCHL is the **most common genetic dyslipidemia**, affecting approximately 1 in 100 to 200 individuals [1]. It is characterized by an overproduction of Apolipoprotein B-100 (ApoB), leading to increased VLDL and LDL. The clinical presentation is highly variable; within the same family (or even the same patient over time), one may see elevated LDL, elevated triglycerides, or both [1]. In this case, the patient presents with isolated LDL elevation and a strong family history of premature CAD, which is a classic presentation of FCHL. **2. Why the other options are incorrect:** * **B. Familial Hypercholesterolemia (FH):** While a major cause of premature CAD, it is less common than FCHL (prevalence ~1 in 250 for heterozygotes) [1]. FH typically presents with much higher LDL levels (>190 mg/dL) and often features physical signs like tendon xanthomas, which are absent here [1]. * **C. Familial Defective Apo B-100:** This involves a mutation in the ligand-binding domain of ApoB-100 [1]. It mimics FH clinically but is significantly rarer. * **D. Apo C-II Deficiency:** This leads to Familial Chylomicronemia Syndrome (Type I Hyperlipoproteinemia). It presents with severe hypertriglyceridemia, eruptive xanthomas, and pancreatitis, rather than isolated high LDL and premature CAD. **Clinical Pearls for NEET-PG:** * **Most common genetic cause of CAD:** Familial Combined Hyperlipidemia. * **Fredrickson Classification:** FCHL is usually Type IIa, IIb, or IV. * **Physical Exam:** Unlike FH (Tendon xanthomas) or Type III (Palmar xanthomas), FCHL usually has **no pathognomonic physical findings** on examination [1]. * **Screening:** Always screen first-degree relatives of patients with premature CAD (Men <55y, Women <65y).

Q: What is true regarding the level of sugar in hyperosmolar non-ketotic hyperglycemia?

Severely elevated. Hyperosmolar Hyperglycemic State (HHS), formerly known as HONK, is a life-threatening complication of Type 2 Diabetes Mellitus. The hallmark of this condition is extreme hyperglycemia, typically much higher than that seen in Diabetic Ketoacidosis (DKA). **Why "Severely Elevated" is correct:** In HHS, there is enough residual insulin to prevent lipolysis and subsequent ketogenesis, but not enough to facilitate glucose uptake by tissues. Because patients do not develop ketoacidosis early, they do not feel "sick" immediately and fail to seek medical attention. This allows the blood glucose to rise unchecked over days or weeks, often exceeding **600 mg/dL** (and frequently reaching >1000 mg/dL). This severe hyperglycemia leads to profound osmotic diuresis and massive dehydration [2]. **Why other options are incorrect:** * **A, B, & C:** These are incorrect because mild or moderate elevations (e.g., 140–300 mg/dL) are characteristic of poorly controlled diabetes or early DKA [3]. HHS is defined by its "hyperosmolar" nature, which is directly driven by the **severe** concentration of glucose in the blood [2]. **High-Yield Clinical Pearls for NEET-PG:** * **Diagnostic Criteria:** Plasma glucose >600 mg/dL, arterial pH >7.30, serum bicarbonate >18 mEq/L, and effective serum osmolality >320 mOsm/kg [2]. * **Key Difference from DKA:** Absence of significant ketosis and a higher degree of dehydration (fluid deficit is often 8–12 Liters). * **Common Trigger:** Infections (e.g., Pneumonia, UTI) are the most common precipitating factors. * **Management Priority:** Aggressive fluid resuscitation (Normal Saline) is the most critical initial step [1], followed by insulin infusion.

Q: Which of the following skin findings is associated with pheochromocytoma?

Cafe-au-lait spots. **Explanation:** The correct answer is **Cafe-au-lait spots**. This association is rooted in the genetic syndromes linked to pheochromocytoma, specifically **Neurofibromatosis Type 1 (NF1)**. Approximately 1–5% of patients with NF1 develop pheochromocytoma. Cafe-au-lait spots are hyperpigmented macules that serve as a hallmark cutaneous marker for NF1, alongside Lisch nodules and neurofibromas. **Analysis of Options:** * **Cafe-au-lait spots (Correct):** Associated with NF1, which is part of the familial clusters of pheochromocytoma (alongside MEN 2A/2B and Von Hippel-Lindau disease). * **Vitiligo:** An autoimmune destruction of melanocytes. While associated with autoimmune polyendocrine syndromes (APS), it has no direct link to pheochromocytoma. * **Ash leaf spots:** These are hypopigmented macules characteristic of **Tuberous Sclerosis**, not pheochromocytoma. * **Acanthosis nigricans:** A marker of **insulin resistance**, often seen in Type 2 Diabetes, PCOS, or gastric malignancy, but not catecholamine-secreting tumors. **Clinical Pearls for NEET-PG:** * **Rule of 10s:** Pheochromocytoma is 10% bilateral, 10% malignant, 10% pediatric, and 10% extra-adrenal (Paraganglioma). * **Genetic Associations:** Remember the mnemonic **"MVN"** for familial cases: **M**EN 2A/2B (RET gene), **V**on Hippel-Lindau (VHL gene), and **N**F1 (NF1 gene) [1]. * **Triad:** The classic clinical triad includes episodic headache, sweating (diaphoresis), and tachycardia. * **Diagnosis:** The best initial screening test is 24-hour urinary fractionated metanephrines or plasma free metanephrines [1].

Q: The Diabetes Control and Complications Trial (DCCT) provided definitive proof that reduction in chronic hyperglycemia helps to improve which of the following?

Microvascular complications of type 1 DM. Explanation: The **Diabetes Control and Complications Trial (DCCT)** is a landmark study in endocrinology that established the relationship between glycemic control and long-term complications [1]. **1. Why Option A is Correct:** The DCCT specifically studied patients with **Type 1 Diabetes Mellitus (T1DM)**. It compared "intensive therapy" (aiming for near-normal glycemia) with "conventional therapy." The trial provided definitive evidence that intensive glycemic control significantly reduces the risk of developing **microvascular complications**, specifically [1]: * **Retinopathy** (reduced risk by ~76%) * **Nephropathy** (reduced albuminuria by ~54%) * **Neuropathy** (reduced by ~60%) **2. Why the other options are incorrect:** * **Options C & D (Type 2 DM):** The DCCT did not study Type 2 DM. The definitive trial for microvascular benefits in **Type 2 DM** was the **UKPDS** (United Kingdom Prospective Diabetes Study) [1]. * **Macrovascular Complications:** While the DCCT showed a trend toward reduced cardiovascular events, it was not statistically significant during the initial trial period. It was only during the long-term follow-up study (**EDIC**) that the "metabolic memory" effect demonstrated a significant reduction in macrovascular events (MI, stroke) in the intensive group. **High-Yield Clinical Pearls for NEET-PG:** * **Metabolic Memory (Legacy Effect):** This concept, derived from DCCT/EDIC and UKPDS, suggests that early intensive glycemic control provides long-term protection against complications, even if control relaxes later. * **DCCT = Type 1 DM** (Microvascular focus). * **UKPDS = Type 2 DM** (Microvascular focus) [1]. * **ACCORD/ADVANCE/VADT:** Trials that showed intensive control in long-standing T2DM does *not* significantly reduce macrovascular outcomes and may increase mortality (ACCORD) [1].

Q: Mauriac's syndrome is characterized by which of the following features, except?

Cardiomegaly. Explanation: Mauriac’s Syndrome is a rare complication of Type 1 Diabetes Mellitus, typically occurring in children and adolescents. It is primarily caused by poor glycemic control and inadequate insulin therapy, leading to a state of intracellular glucose deprivation despite extracellular hyperglycemia [1]. Why Cardiomegaly is the correct answer: Cardiomegaly is not a feature of Mauriac’s Syndrome. The hallmark of the condition is Hepatomegaly (due to glycogen deposition in the liver, known as glycogenic hepatopathy). While the syndrome involves multiple organ systems, the heart is generally spared from structural enlargement. Analysis of other options: * Diabetes (Option A): This is the underlying prerequisite. The syndrome occurs exclusively in patients with poorly controlled Type 1 Diabetes [1]. * Obesity (Option B): Patients typically present with a "Cushingoid" appearance, characterized by centripetal obesity, moon facies, and a buffalo hump. This occurs because the fluctuating levels of insulin and high cortisol/growth hormone levels (counter-regulatory response) promote fat redistribution. * Dwarfism (Option C): Growth failure and delayed puberty are classic features. The lack of adequate insulin (which acts as an anabolic hormone) and suppressed IGF-1 levels lead to growth retardation or "diabetic dwarfism." High-Yield Clinical Pearls for NEET-PG: * The Triad: Hepatomegaly, Growth Failure (Dwarfism), and Cashingoid features in a Type 1 Diabetic. * Pathophysiology: Repeated cycles of hyperglycemia followed by high-dose insulin leads to massive glycogen trapping in hepatocytes. * Reversibility: Unlike many diabetic complications, Mauriac’s Syndrome is largely reversible with optimized, consistent glycemic control and modern insulin regimens. * Biochemical marker: Elevated transaminases (AST/ALT) are common, but unlike cirrhosis, there is no progression to fibrosis.

Question 1

Which of the following is NOT a feature of hyperparathyroidism?

Accepted Answer

Diarrhea

Answer

Increased serum calcium

Answer

Decreased serum phosphate

Answer

Nephrocalcinosis

Question 2

Which of the following statements regarding SIADH is FALSE?

Accepted Answer

Vaptans are new FDA-approved drugs for its treatment.

Answer

Serum sodium can be less than 135 mEq/L.

Answer

Urine sodium is normal or slightly low.

Answer

Water loading test can be used.

Question 3

A 25-year-old man requests cholesterol screening due to a family history of premature coronary artery disease (CAD). His lipid levels reveal elevated total and LDL cholesterol, with normal HDL and triglyceride values. His physical examination is normal. What is the most common cause of genetic dyslipidemia?

Accepted Answer

Familial combined hyperlipidemia

Answer

Familial hypercholesterolemia

Answer

Familial defective Apo B

Answer

Apo C-II deficiency

Question 4

What is true regarding the level of sugar in hyperosmolar non-ketotic hyperglycemia?

Accepted Answer

Severely elevated

Answer

No change

Answer

Mild elevation

Answer

Moderate elevation

Question 5

A 30-year-old woman presented with secondary amenorrhea for 3 years along with galactorrhea. What is the most likely cause of her symptoms?

Accepted Answer

Prolactinoma

Answer

Craniopharyngioma

Answer

Meningioma

Answer

Subarachnoid hemorrhage

Question 6

Which of the following skin findings is associated with pheochromocytoma?

Accepted Answer

Cafe-au-lait spots

Answer

Vitiligo

Answer

Ash leaf spots

Answer

Acanthosis nigricans

Question 7

Which of the following is NOT true of cerebral salt wasting?

Accepted Answer

Low uric acid in serum

Answer

Increased urine output

Answer

Low intravascular volume

Answer

Decreased vasopressin levels

Question 8

A 19-year-old woman presents with primary amenorrhea. Her physical examination is normal, showing female sex characteristics and breast development. The only abnormality noted is the absence of body hair. Genetic testing reveals an XY chromosome pattern. Which of the following mechanisms is most likely to explain her phenotypic pattern and amenorrhea?

Accepted Answer

Androgen receptor defect

Answer

Estrogen receptor defect

Answer

Excess hormone production

Answer

Decreased hormone production

Question 9

The Diabetes Control and Complications Trial (DCCT) provided definitive proof that reduction in chronic hyperglycemia helps to improve which of the following?

Accepted Answer

Microvascular complications of type 1 DM

Answer

Microvascular complications of type 2 DM

Answer

Macrovascular complications of type 2 DM

Question 10

Mauriac's syndrome is characterized by which of the following features, except?

Accepted Answer

Cardiomegaly

Answer

Diabetes

Answer

Obesity

Answer

Dwarfism

Endocrinology — MCQs

Endocrinology — MCQs

On this page

Practice by Chapter

Want unlimited practice?